Jean Charles Fruchart

Summary

Affiliation: Institut Pasteur de Lille
Country: France

Publications

  1. ncbi Peroxisome proliferator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis
    J C Fruchart
    Department of Atherosclerosis, INSERM U325, Pasteur Institute, University of Lille II, France
    Curr Opin Lipidol 10:245-57. 1999
  2. ncbi HDL and triglyceride as therapeutic targets
    Jean Charles Fruchart
    Departement de Recherche sur les Lipoproteines et l Atherosclerose, INSERM U545, Institut Pasteur de Lille et Faculté de Pharmacie, Universite de Lille, France
    Curr Opin Lipidol 13:605-16. 2002
  3. doi Peroxisome proliferator-activated receptor-alpha (PPARalpha): at the crossroads of obesity, diabetes and cardiovascular disease
    Jean Charles Fruchart
    Laboratoire J and K, INSERM UR 545, Universite Lille 2, Faculte de Medecine de Lille, Pole Recherche, Lille Cedex, France
    Atherosclerosis 205:1-8. 2009
  4. ncbi Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism
    Jean Charles Fruchart
    Lipoprotein and Atherosclerosis Research Unit, INSERM Unité de Recherche sur l Arthérosclérose and Lille University 2 U545, Pasteur Institute of Lille, Lille, France
    Drugs Today (Barc) 42:39-64. 2006
  5. ncbi New risk factors for atherosclerosis and patient risk assessment
    Jean Charles Fruchart
    Departement de Recherche sur les Lipoproteines et l Atherosclerose, Pasteur de Lille, Inserm U545 et Faculté de Pharmacie, université du droit et de la santé de Lille 2, Lille, France
    Circulation 109:III15-9. 2004
  6. ncbi Peroxisome proliferator activated receptors and stroke
    Jean Charles Fruchart
    Unité de Recherche sur les Lipoprotéines et l Athérosclérose, UR 545 INSERM and Université de Lille 2, Institut Pasteur, 1 rue du Pr Calmette, 59019 Lille, France
    Curr Atheroscler Rep 5:331-2. 2003
  7. ncbi Novel peroxisome proliferator activated receptor-alpha agonists
    Jean Charles Fruchart
    Department of Atherosclerosis, Institut Pasteur de Lille, and University of Lille 2, Lille, France
    Am J Cardiol 100:n41-6. 2007
  8. doi The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient
    Jean Charles Fruchart
    INSERM UR 545, Universite Lille 2, Lille, France
    Diab Vasc Dis Res 5:319-35. 2008
  9. doi The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia
    Jean Charles Fruchart
    INSERM UR 545, Institut Pasteur de Lille, Universite Lille 2, Lille, France
    Am J Cardiol 102:1K-34K. 2008
  10. ncbi [Anti-cholesterol agents, new therapeutic approaches]
    J C Fruchart
    Unité de Recherche sur les Lipoprotéines et l Athérosclérose, Institut Pasteur de Lille, INSERM U545, Faculte de Pharmacie, Universite de Lille II, 1, rue du Professeur Calmette, BP 245, F59019 Lille
    Ann Pharm Fr 62:3-18. 2004

Detail Information

Publications107 found, 100 shown here

  1. ncbi Peroxisome proliferator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis
    J C Fruchart
    Department of Atherosclerosis, INSERM U325, Pasteur Institute, University of Lille II, France
    Curr Opin Lipidol 10:245-57. 1999
    ....
  2. ncbi HDL and triglyceride as therapeutic targets
    Jean Charles Fruchart
    Departement de Recherche sur les Lipoproteines et l Atherosclerose, INSERM U545, Institut Pasteur de Lille et Faculté de Pharmacie, Universite de Lille, France
    Curr Opin Lipidol 13:605-16. 2002
    ..The goal of this review is to discuss if triglycerides and HDL-cholesterol could be therapeutic targets to reduce cardiovascular risk...
  3. doi Peroxisome proliferator-activated receptor-alpha (PPARalpha): at the crossroads of obesity, diabetes and cardiovascular disease
    Jean Charles Fruchart
    Laboratoire J and K, INSERM UR 545, Universite Lille 2, Faculte de Medecine de Lille, Pole Recherche, Lille Cedex, France
    Atherosclerosis 205:1-8. 2009
    ..It is anticipated that PPARalpha will continue to have important clinical application in addressing the major challenge of cardiometabolic risk associated with type 2 diabetes, obesity and metabolic syndrome...
  4. ncbi Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism
    Jean Charles Fruchart
    Lipoprotein and Atherosclerosis Research Unit, INSERM Unité de Recherche sur l Arthérosclérose and Lille University 2 U545, Pasteur Institute of Lille, Lille, France
    Drugs Today (Barc) 42:39-64. 2006
    ..PPARs are also expressed in atherosclerotic lesions...
  5. ncbi New risk factors for atherosclerosis and patient risk assessment
    Jean Charles Fruchart
    Departement de Recherche sur les Lipoproteines et l Atherosclerose, Pasteur de Lille, Inserm U545 et Faculté de Pharmacie, université du droit et de la santé de Lille 2, Lille, France
    Circulation 109:III15-9. 2004
    ....
  6. ncbi Peroxisome proliferator activated receptors and stroke
    Jean Charles Fruchart
    Unité de Recherche sur les Lipoprotéines et l Athérosclérose, UR 545 INSERM and Université de Lille 2, Institut Pasteur, 1 rue du Pr Calmette, 59019 Lille, France
    Curr Atheroscler Rep 5:331-2. 2003
  7. ncbi Novel peroxisome proliferator activated receptor-alpha agonists
    Jean Charles Fruchart
    Department of Atherosclerosis, Institut Pasteur de Lille, and University of Lille 2, Lille, France
    Am J Cardiol 100:n41-6. 2007
    ..This article discusses the role of PPARs in the treatment of cardiometabolic abnormalities involved in cardiovascular risk...
  8. doi The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient
    Jean Charles Fruchart
    INSERM UR 545, Universite Lille 2, Lille, France
    Diab Vasc Dis Res 5:319-35. 2008
    ..In conclusion, the R3I highlights the need to address with lifestyle and/or pharmacotherapy the high level of residual vascular risk among dyslipidaemic patients who are treated in accordance with current standards of care...
  9. doi The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia
    Jean Charles Fruchart
    INSERM UR 545, Institut Pasteur de Lille, Universite Lille 2, Lille, France
    Am J Cardiol 102:1K-34K. 2008
    ....
  10. ncbi [Anti-cholesterol agents, new therapeutic approaches]
    J C Fruchart
    Unité de Recherche sur les Lipoprotéines et l Athérosclérose, Institut Pasteur de Lille, INSERM U545, Faculte de Pharmacie, Universite de Lille II, 1, rue du Professeur Calmette, BP 245, F59019 Lille
    Ann Pharm Fr 62:3-18. 2004
    ..Therefore the mechanisms of action of statins and fibrates depend on their capacity to modulate the expression of genes controlling lipoprotein metabolism...
  11. ncbi Peroxisome proliferator-activated receptor-alpha activation and high-density lipoprotein metabolism
    J C Fruchart
    Department of Atherosclerosis, Pasteur Institute of Lille, UR 545 INSERM, Lille, France
    Am J Cardiol 88:24N-29N. 2001
    ..Increased HDL synthesis, accelerated efflux of cholesterol, and its hepatic uptake are the ultimate outcome of fibrate influence, with a consequent enhancement of the protective effect of HDL cholesterol...
  12. ncbi PPARS, metabolic disease and atherosclerosis
    J C Fruchart
    Unité de Recherche sur les Lipoprotéines et l Athérosclérose, Faculte de Pharmacie, INSERM U545, Institut Pasteur et Université de Lille 2, Lille, France
    Pharmacol Res 44:345-52. 2001
    ....
  13. ncbi [Statins for cardiovascular prevention. Lowering LDL cholesterol, the primary objective]
    Jean Charles Fruchart
    Departement de Recherche sur les Lipoproteines et l Atherosclerose, UR 545 Inserm et Université de Lille 2, Institut Pasteur 1, rue du Professeur Calmette 59019 Lille
    Presse Med 31:1428-33. 2002
    ..Nonetheless, the other risk factors must also be treated in order to reduce the patients' global cardiovascular risk score...
  14. ncbi The UDP-glucuronosyltransferase 1A9 enzyme is a peroxisome proliferator-activated receptor alpha and gamma target gene
    Olivier Barbier
    UR 545 INSERM, Departement d Atherosclerose, Institut Pasteur de Lille and the Faculté de Pharmacie, Universite de Lille II, France
    J Biol Chem 278:13975-83. 2003
    ..Furthermore, since UGT1A9 is involved in the catabolism of fibrates, these results suggest that PPAR alpha and PPAR gamma may control the intracellular level of active fibrates...
  15. ncbi Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression
    Thierry Claudel
    UR545 INSERM, Departement d Atherosclerose, Institut Pasteur de Lille, Lille, France
    Gastroenterology 125:544-55. 2003
    ..Apolipoprotein CIII (Apo CIII) is a determinant of serum triglyceride metabolism. In this study, we investigated whether activators of the nuclear farnesoid X receptor (FXR) modulate Apo CIII gene expression...
  16. pmc Bile acid-activated nuclear receptor FXR suppresses apolipoprotein A-I transcription via a negative FXR response element
    Thierry Claudel
    Unité de Recherche 545, Institut National de la Sante et de la Recherche Medicale, Departement d Atherosclerose, Institut Pasteur de Lille, and the Faculté de Pharmacie, Universite de Lille II, Lille, France
    J Clin Invest 109:961-71. 2002
    ..FXR bound this site and repressed transcription in a manner independent of retinoid X receptor. The nonsteroidal synthetic FXR agonist GW4064 likewise decreased apoA-I mRNA levels and promoter activity in HepG2 cells...
  17. ncbi Peroxisome proliferator-activated receptor alpha induces hepatic expression of the human bile acid glucuronidating UDP-glucuronosyltransferase 2B4 enzyme
    Olivier Barbier
    Unité de Recherche 545, Institut National de la Sante et de la Recherche Medicale, Departement d Atherosclerose, Institut Pasteur de Lille and the Faculté de Pharmacie, Universite de Lille II, 59019 Lille, France
    J Biol Chem 278:32852-60. 2003
    ....
  18. ncbi The liver X receptor ligand T0901317 down-regulates APOA5 gene expression through activation of SREBP-1c
    Heidelinde Jakel
    Departement d Atherosclerose, UR545 INSERM, Institut Pasteur de Lille and Faculté de Pharmacie de Lille, 1 rue du Pr Calmette BP 245, 59019 Lille Cedex, France, Genfit SA, Loos F 59120, France
    J Biol Chem 279:45462-9. 2004
    ....
  19. ncbi The RXR agonist bexarotene improves cholesterol homeostasis and inhibits atherosclerosis progression in a mouse model of mixed dyslipidemia
    Fanny Lalloyer
    Institut Pasteur de Lille, Departement d Atherosclerose, Lille, France
    Arterioscler Thromb Vasc Biol 26:2731-7. 2006
    ..Here, we investigated the effect of bexarotene on atherosclerosis progression in a dyslipidemic murine model, the human apolipoprotein E2 knockin mouse, that develops essentially macrophage-laden lesions...
  20. ncbi Transcriptional regulation of human Rev-erbalpha gene expression by the orphan nuclear receptor retinoic acid-related orphan receptor alpha
    Eric Raspé
    UR 545 INSERM, Institut Pasteur de Lille, 1 rue du Pr Calmette, 59019 Lille, France
    J Biol Chem 277:49275-81. 2002
    ..Finally, adenoviral overexpression of hRORalpha1 in HepG2 cells led to enhanced hRev-erbalpha mRNA accumulation, further confirming the physiological importance of RORalpha1 in the regulation of Rev-erbalpha expression...
  21. ncbi The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice
    Bertrand Cariou
    Institut Pasteur de Lille, Departement d Atherosclerose, Lille, F 59019, France
    J Biol Chem 281:11039-49. 2006
    ..This unexpected function of FXR opens new perspectives for the treatment of type 2 diabetes...
  22. ncbi Bile acids induce the expression of the human peroxisome proliferator-activated receptor alpha gene via activation of the farnesoid X receptor
    Ines Pineda Torra
    U 545 Institut National de la Santé et de la Recherche Médicale, Departement d Atherosclerose, Institut Pasteur de Lille, 59019 Lille, France
    Mol Endocrinol 17:259-72. 2003
    ..These results provide molecular evidence for a cross-talk between the FXR and PPARalpha pathways in humans...
  23. ncbi Characterization of the human PPARalpha promoter: identification of a functional nuclear receptor response element
    Ines Pineda Torra
    U 545 Institut National de la Santé et de la Recherche Médicale, Departement d Atherosclerose, Institut Pasteur de Lille, 59019 Lille, France
    Mol Endocrinol 16:1013-28. 2002
    ..Furthermore, these data demonstrate that the hPPARalpha gene is regulated by nuclear receptors, such as HNF-4, COUP-TFII, and PPARalpha...
  24. ncbi Glucose regulates the expression of the farnesoid X receptor in liver
    Daniel Duran-Sandoval
    Atherosclerosis Department, Unité de Recherche 545 Institute National de la Santé et de la Recherche Médicale, Pasteur Institute of Lille, and Faculty of Pharmacy, Lille2 University, Lille, France
    Diabetes 53:890-8. 2004
    ..In addition, FXR is regulated by glucose likely via the pentose phosphate pathway. Dysregulation of FXR expression may contribute to alterations in lipid and bile acid metabolism in patients with diabetes or insulin resistance...
  25. ncbi Transient impairment of the adaptive response to fasting in FXR-deficient mice
    Bertrand Cariou
    Research Unit 545 INSERM, Atherosclerosis Department, Pasteur Institute of Lille, Faculty of Pharmacy, Lille2 University, Lille, France
    FEBS Lett 579:4076-80. 2005
    ..Moreover, hepatic PEPCK gene expression was transiently lower in FXR-/- mice after 6h of fasting and was decreased in FXR-/- hepatocytes. FXR therefore plays an unexpected role in the control of fuel availability upon fasting...
  26. ncbi PPARalpha, but not PPARgamma, activators decrease macrophage-laden atherosclerotic lesions in a nondiabetic mouse model of mixed dyslipidemia
    Nathalie Hennuyer
    INSERM U545, Departement d Atherosclerose, Institut Pasteur de Lille, 1 rue du Professeur Calmette, 59019 Lille Cedex, France
    Arterioscler Thromb Vasc Biol 25:1897-902. 2005
    ....
  27. ncbi Daily melatonin supplementation in mice increases atherosclerosis in proximal aorta
    Anne Tailleux
    Departement d Atherosclerose, INSERM U545, Institut Pasteur, 1 rue du Pr Calmette, 59019 Lille, France
    Biochem Biophys Res Commun 293:1114-23. 2002
    ..This study suggests that caution should be taken as regards high melatonin dosage in hypercholesterolemic patients...
  28. ncbi Adipophilin enhances lipid accumulation and prevents lipid efflux from THP-1 macrophages: potential role in atherogenesis
    Guilhem Larigauderie
    Department of Atherosclerosis, SERLIA INSERM UR545, Institut Pasteur de Lille, Lille, France
    Arterioscler Thromb Vasc Biol 24:504-10. 2004
    ..In this study, we investigated the function of adipophilin in lipid accumulation and cholesterol efflux in THP-1 macrophages...
  29. ncbi Perilipin, a potential substitute for adipophilin in triglyceride storage in human macrophages
    Guilhem Larigauderie
    INSERM, U545, Institut Pasteur de Lille, Departement d Atherosclerose, Lille F 59019, France Université de Lille 2, Lille F 59006, France
    Atherosclerosis 189:142-8. 2006
    ..Therefore, inhibition of adipophilin might not be sufficient to prevent lesion formation as previously suggested, and perilipin inhibition might be additionally required...
  30. ncbi Lipid free apolipoprotein E binds to the class B Type I scavenger receptor I (SR-BI) and enhances cholesteryl ester uptake from lipoproteins
    Stéphanie Bultel-Brienne
    Unité INSERM U 545, Institut Pasteur de Lille, Faculte de Pharmacie, Universite Lille 2, 1 rue du Professeur Calmette, 59019 Lille Cedex, France
    J Biol Chem 277:36092-9. 2002
    ..We propose that this direct interaction could modify SR-BI structure in cell membranes and potentiate CE uptake...
  31. ncbi Peroxisome proliferator-activated receptor alpha induces NADPH oxidase activity in macrophages, leading to the generation of LDL with PPAR-alpha activation properties
    Elisabeth Teissier
    UR 545 INSERM Institut Pasteur de Lille and Faculté de Pharmacie, Universite de Lille II, Lille, France
    Circ Res 95:1174-82. 2004
    ..These data identify a novel mechanism of autogeneration of endogenous PPAR-alpha ligands via stimulation of NADPH oxidase activity...
  32. ncbi C-reactive protein, interleukin-6, and fibrinogen as predictors of coronary heart disease: the PRIME Study
    Gerald Luc
    Department of Atherosclerosis, SERLIA INSERM UR545, Institut Pasteur de Lille and University Lille II, 1 rue du Professeur Calmette, 59019 Lille Cedex, France
    Arterioscler Thromb Vasc Biol 23:1255-61. 2003
    ....
  33. ncbi FXR induces the UGT2B4 enzyme in hepatocytes: a potential mechanism of negative feedback control of FXR activity
    Olivier Barbier
    U545 INSERM, Department of Atherosclerosis, Faculty of Pharmacy, Lille Pasteur Institute and University of Lille II, 1 rue du Pr Calmette, BP 245, 59019 Lille, France
    Gastroenterology 124:1926-40. 2003
    ..The human uridine 5'-diphosphate-glucuronosyltransferase 2B4 (UGT2B4) converts hydrophobic bile acids into more hydrophilic glucuronide derivatives. In this study, we identify UGT2B4 as an FXR target gene...
  34. ncbi Mechanism of triglyceride lowering in mice expressing human apolipoprotein A5
    Jamila Fruchart-Najib
    Departement d Atherosclerose, UR 545 INSERM, Institut Pasteur de Lille et Université de Lille II, 1 rue du Pr Calmette BP 245, 59019 Lille Cedex, France
    Biochem Biophys Res Commun 319:397-404. 2004
    ..This shift of apoAV in VLDL appears to limit the increase of triglyceride by activating the lipoprotein lipase...
  35. ncbi Different ways to regulate the PPARalpha stability
    Christophe Blanquart
    INSERM UR 545, Departement d Atherosclerose, Institut Pasteur de Lille, 1 rue du Pr Calmette, 59019 Lille, France
    Biochem Biophys Res Commun 319:663-70. 2004
    ..These data indicate that heterodimerization, recruitment of cofactors, and post-translational modifications can modulate the stability of PPARalpha...
  36. ncbi Value of HDL cholesterol, apolipoprotein A-I, lipoprotein A-I, and lipoprotein A-I/A-II in prediction of coronary heart disease: the PRIME Study. Prospective Epidemiological Study of Myocardial Infarction
    Gerald Luc
    Department of Atherosclerosis, INSERM UR545, Institut Pasteur de Lille, and University Lille II, Lille, France
    Arterioscler Thromb Vasc Biol 22:1155-61. 2002
    ..We have examined the association between the incidence of coronary heart disease (CHD) and plasma high density lipoprotein (HDL) cholesterol, apolipoprotein A-I (apoA-I), and 2 HDL fractions, lipoprotein A-I and lipoprotein A-I:A-II...
  37. ncbi Peroxisome proliferator-activated receptor alpha (PPARalpha ) turnover by the ubiquitin-proteasome system controls the ligand-induced expression level of its target genes
    Christophe Blanquart
    INSERM UR 545, Departement d Atherosclerose, Institut Pasteur de Lille, 1 rue du Pr Calmette 59019 Lille, France
    J Biol Chem 277:37254-9. 2002
    ..Regulation of its degradation provides a novel regulatory mechanism of transcriptional activity of this nuclear receptor...
  38. ncbi Circulating soluble adhesion molecules ICAM-1 and VCAM-1 and incident coronary heart disease: the PRIME Study
    Gerald Luc
    Department of Atherosclerosis, SERLIA INSERM UR325, Institut Pasteur de Lille, 1, rue du Professeur Calmette, 59019 Lille, France
    Atherosclerosis 170:169-76. 2003
    ....
  39. ncbi Transcriptional regulation of apolipoprotein A5 gene expression by the nuclear receptor RORalpha
    Annelise Genoux
    Departement d Atherosclerose, U 545 INSERM, Institut Pasteur de Lille and Faculté de Pharmacie de Lille, Lille Cedex, France
    Arterioscler Thromb Vasc Biol 25:1186-92. 2005
    ..In the present study, we identified the retinoic acid receptor-related orphan receptor-alpha (RORalpha) as a regulator of human APOA5 gene expression...
  40. ncbi The protein kinase C signaling pathway regulates a molecular switch between transactivation and transrepression activity of the peroxisome proliferator-activated receptor alpha
    Christophe Blanquart
    UR 545 Institut National de la Santé et de la Recherche Médicale, Departement d Atherosclerose, Institut Pasteur de Lille, 1 rue du Pr Calmette, 59019 Lille, France
    Mol Endocrinol 18:1906-18. 2004
    ..Altogether, our data indicate that the PKC signaling pathway acts as a molecular switch dissociating the transactivation and transrepression functions of PPARalpha, which involved phosphorylation of serines 179 and 230...
  41. ncbi Rosuvastatin reduces MMP-7 secretion by human monocyte-derived macrophages: potential relevance to atherosclerotic plaque stability
    Christophe Furman
    INSERM U 545 and Institut Pasteur de Lille, 1 rue du Professeur Calmette, BP 245, 59019 Lille Cedex, France
    Atherosclerosis 174:93-8. 2004
    ..The effect of rosuvastatin in reducing MMP-7 might protect fibrous caps from degradation and in turn stabilize atheromatous plaques...
  42. ncbi Modulation of hepatic inflammatory risk markers of cardiovascular diseases by PPAR-alpha activators: clinical and experimental evidence
    Alberto Zambon
    Departement d Atherosclerose, Institut Pasteur de Lille, Lille, France
    Arterioscler Thromb Vasc Biol 26:977-86. 2006
    ....
  43. ncbi Regulation of the scavenger receptor BI and the LDL receptor by activators of aldosterone production, angiotensin II and PMA, in the human NCI-H295R adrenocortical cell line
    Antoine Pilon
    INSERM U545, Institut Pasteur de Lille and Faculté de Pharmacie, Universite de Lille 2, 59019, Lille, France
    Biochim Biophys Acta 1631:218-28. 2003
    ....
  44. ncbi Is apolipoprotein A5 a novel regulator of triglyceride-rich lipoproteins?
    Heidelinde Jakel
    Departement d Atherosclerose, UR545 INSERM, Universite de Lille II, Loos, France
    Ann Med 38:2-10. 2006
    ..This review aims to give a comprehensive summary of the current literature and supports the view that APOA5 plays a relevant role in lipid metabolism...
  45. ncbi Peroxisome proliferator-activated receptors: new targets for the pharmacological modulation of macrophage gene expression and function
    Giulia Chinetti
    Institut Pasteur de Lille, UR 545 INSERM, Lille, France and Université de Lille 2, Lille, France
    Curr Opin Lipidol 14:459-68. 2003
    ....
  46. ncbi The plasma and lipoprotein triglyceride postprandial response to a carbohydrate tolerance test differs in lean and massively obese normolipidemic women
    Jean Dallongeville
    INSERM U 508, Institut Pasteur de Lille, France
    J Nutr 132:2161-6. 2002
    ..The carbohydrate load did not affect apoB-100 and apoB-48 levels. These findings suggest that postprandial triglyceride metabolism is impaired after a carbohydrate load in normolipidemic massively obese women...
  47. ncbi Potential regulatory role of the farnesoid X receptor in the metabolic syndrome
    Daniel Duran-Sandoval
    U R 545 INSERM, Département d Atherosclerosis, Institut Pasteur de Lille et Faculté de Pharmacie, Universite de Lille 2, 1, rue du Professeur Calmette, BP245, 59019 Lille, France
    Biochimie 87:93-8. 2005
    ..These observations raise the intriguing possibility for a modulatory role of this receptor also in the metabolic syndrome...
  48. ncbi Identification of Rev-erbalpha as a physiological repressor of apoC-III gene transcription
    Eric Raspé
    UR 545 INSERM, Institut Pasteur de Lille, 1 rue Calmette, 59019 Lille, France
    J Lipid Res 43:2172-9. 2002
    ..Taken together, our data identify Rev-erbalpha as a regulator of apoC-III gene expression, providing a novel, physiological role for this nuclear receptor in the regulation of lipid metabolism...
  49. ncbi Extracellular human thioredoxin-1 inhibits lipopolysaccharide-induced interleukin-1beta expression in human monocyte-derived macrophages
    Ludivine Billiet
    U 545 INSERM, Institut Pasteur de Lille and Université Lille 2, 59019 Lille, France
    J Biol Chem 280:40310-8. 2005
    ..Taken together, these data indicated a potential new mechanism through which extracellular rhTrx-1 exerts an anti-inflammatory function in HMDM...
  50. ncbi Characterization of a new mouse model for human apolipoprotein A-I/C-III/A-IV deficiency
    Hafid Mezdour
    Laboratoire de Génétique Expérimentale, Institut Pasteur de Lille, France
    J Lipid Res 47:912-20. 2006
    ..e., marked hypoalphalipoproteinemia) and provide further support for the apoa1/c3/a4 gene cluster as a minor susceptibility locus for atherosclerosis in mice...
  51. ncbi Hepatic expression of the UGT1A9 gene is governed by hepatocyte nuclear factor 4alpha
    Olivier Barbier
    Unité INSERM 545, Institut Pasteur de Lille, 1 rue du Pr Calmette, BP 245, 59019 Lille, France
    Mol Pharmacol 67:241-9. 2005
    ....
  52. ncbi SR-BI does not require raft/caveola localisation for cholesteryl ester selective uptake in the human adrenal cell line NCI-H295R
    Olivier Briand
    INSERM UR545, Institut Pasteur de Lille and Faculté des Sciences Pharmaceutiques et Biologiques, Universite de Lille 2, 1 rue du Professeur Calmette BP245, 59019, Lille, France
    Biochim Biophys Acta 1631:42-50. 2003
    ..In conclusion, we provide evidence that SR-BI does not require raft/caveola localisation to be implicated in CE selective uptake either in basal or in induced conditions...
  53. ncbi DNA binding-independent induction of IkappaBalpha gene transcription by PPARalpha
    Philippe Delerive
    Institut National de la Santé et de la Recherche Médicale U 545, Departement d Atherosclerose, Institut Pasteur de Lille, 59019 Lille, France
    Mol Endocrinol 16:1029-39. 2002
    ....
  54. ncbi HMG-CoA reductase inhibition and PPAR- alpha activation both inhibit cyclosporin A induced endothelin-1 secretion in cultured endothelial cells
    Abdelmejid Kandoussi
    Département de Recherches sur les Lipoprotéines et l Athérosclérose, INSERM U545, Institut Pasteur de Lille, 1 rue du Professeur Calmette, BP 245, 59019, Lille, France
    Clin Sci (Lond) 103:81S-83S. 2002
    ..Furthermore, we suggest that the mevalonate metabolism would interfere with PPAR-alpha activity...
  55. ncbi Liver X receptor activation potentiates the lipopolysaccharide response in human macrophages
    Coralie Fontaine
    Institut Pasteur de Lille, Departement d Atherosclerose, Lille, France
    Circ Res 101:40-9. 2007
    ..These data provide evidence for an immunomodulatory function of LXRs in human macrophages via mechanisms distinct from those previously identified in mouse macrophages...
  56. ncbi Murine models to investigate pharmacological compounds acting as ligands of PPARs in dyslipidemia and atherosclerosis
    Anne Tailleux
    Unité de Recherche INSERM 545, Departement d Atherosclerose, Institut Pasteur de Lille, France
    Trends Pharmacol Sci 24:530-4. 2003
  57. ncbi Increased susceptibility of low-density lipoprotein to ex vivo oxidation in mice transgenic for human apolipoprotein B treated with 1 melatonin-related compound is not associated with atherosclerosis progression
    Anne Tailleux
    Département de Recherches sur l Athérosclérose, INSERM U545, Institut Pasteur de Lille, Lille, France
    J Cardiovasc Pharmacol 46:241-9. 2005
    ..These data confirm that the capacity of molecules to inhibit atherogenic lipoprotein oxidation in vitro offers no prediction of their capacity to inhibit in vivo atherosclerosis development...
  58. ncbi Therapeutic roles of peroxisome proliferator-activated receptor agonists
    Bart Staels
    Department of Atherosclerosis, Unité INSERM 545 Institut Pasteur, 1, rue du Professeur Calmette, 59019 Lille Cedex, France
    Diabetes 54:2460-70. 2005
    ..The functions of a third PPAR isoform, PPARdelta, and its potential as a therapeutic target are currently under investigation...
  59. ncbi Lipoprotein (a) as a predictor of coronary heart disease: the PRIME Study
    Gerald Luc
    Department of Atherosclerosis, INSERM UR545, Pasteur Institute of Lille, 1, rue du Professeur Calmette, France and University Lille II, France
    Atherosclerosis 163:377-84. 2002
    ..This study which analyzed Lp(a) level using a measurement independent of apolipoprotein (a) size on fresh plasma, has confirmed utility of Lp(a) as a predictor of CHD...
  60. ncbi Natural phenylpropanoids protect endothelial cells against oxidized LDL-induced cytotoxicity
    Françoise Martin-Nizard
    Département de Recherches sur les Lipoprotéines et l Athérosclérose, Institut Pasteur, INSERM UR 545 et Faculté de Pharmacie, Universite de Lille 2, Lille, France
    Planta Med 69:207-11. 2003
    ..These data suggest that natural phenylpropanoids inhibit mOx-LDL-induced cellular toxicity and that inhibition of lipid peroxidation could be a key mechanism in the cytoprotective effect of these molecules...
  61. ncbi Natural phenylpropanoids inhibit lipoprotein-induced endothelin-1 secretion by endothelial cells
    Françoise Martin-Nizard
    Departement de Recherche sur les Lipoproteines et l Atherosclerose, INSERM UR 545, Institut Pasteur, 1, rue du Professeue Calmette, B P 245, 59019 Lille Cedex, France
    J Pharm Pharmacol 56:1607-11. 2004
    ..Since ET-1 plays an important role in atherosclerosis development, our work suggests that the tested phenylpropanoids could have a beneficial effect in inhibiting atherosclerosis development...
  62. ncbi Apolipoprotein A-II, HDL metabolism and atherosclerosis
    Anne Tailleux
    Faculte de Pharmacie, Département d athérosclérose et INSERM U 545, Institut Pasteur, Universite Lille 2, 1, rue du Professeur Calmette, 59019 Cedex, Lille, France
    Atherosclerosis 164:1-13. 2002
    ..It can be suggested that apo A-II is not a strong determinant of lipid metabolism, but is rather a modulator of reverse cholesterol transport...
  63. ncbi Acute antiinflammatory properties of statins involve peroxisome proliferator-activated receptor-alpha via inhibition of the protein kinase C signaling pathway
    Rejane Paumelle
    Institut Pasteur de Lille, Departement d Atherosclerose, INSERM, U545, Lille, France
    Circ Res 98:361-9. 2006
    ..These data indicate that the acute antiinflammatory effect of simvastatin occurs via PPARalpha by a mechanism involving inhibition of PKCalpha inactivation of PPARalpha transrepression activity...
  64. ncbi The orphan nuclear receptor Rev-Erbalpha is a peroxisome proliferator-activated receptor (PPAR) gamma target gene and promotes PPARgamma-induced adipocyte differentiation
    Coralie Fontaine
    UR545 INSERM, Departement d Atherosclerose, 1, rue Calmette, Institut Pasteur de Lille, 59019 Lille, France
    J Biol Chem 278:37672-80. 2003
    ..These results identify Rev-Erbalpha as a target gene of PPARgamma in adipose tissue and demonstrate a role for this nuclear receptor as a promoter of adipocyte differentiation...
  65. ncbi Liver X receptors: new players in atherogenesis?
    Virginie Bocher
    UMR 545 INSERM, Department of Atherosclerosis, Lille Pasteur Institute, Lille, France, and Faculty of Pharmacy, University of Lille II, Lille, France
    Curr Opin Lipidol 14:137-43. 2003
    ..In this review, we describe the most recent developments concerning their functions in cholesterol and lipid metabolism and their impact in atherogenesis...
  66. pmc PPAR alpha inhibits vascular smooth muscle cell proliferation underlying intimal hyperplasia by inducing the tumor suppressor p16INK4a
    Florence Gizard
    INSERM U545, Departement d Atherosclerose, Institut Pasteur de Lille et Faculté de Pharmacie, université Lille II, Lille, France
    J Clin Invest 115:3228-38. 2005
    ..Thus, the PPARalpha/p16 pathway may be a potential pharmacological target for the prevention of cardiovascular occlusive complications of atherosclerosis...
  67. ncbi Peroxisome proliferator-activated receptor alpha improves pancreatic adaptation to insulin resistance in obese mice and reduces lipotoxicity in human islets
    Fanny Lalloyer
    Institut Pasteur de Lille, Departement d Atherosclerose, Lille, France
    Diabetes 55:1605-13. 2006
    ..These results indicate that PPARalpha improves the adaptative response of the pancreatic beta-cell to pathological conditions. PPARalpha could thus represent a promising target in the prevention of type 2 diabetes...
  68. ncbi Glucose regulates LXRalpha subcellular localization and function in rat pancreatic beta-cells
    Audrey Helleboid-Chapman
    Atherosclerosis Department, UR 545 INSERM, The Faculty of Pharmacy, Lille 2 University, 1 rue du Professeur Calmette BP245, Lille Cedex 59019, France
    Cell Res 16:661-70. 2006
    ..2 mM glucose in a dose-dependent manner. Furthermore, at low glucose condition, okadaic acid reversed LXRalpha effect on insulin secretion, suggesting the involvement of glucose signaling through a phosphorylation-dependent mechanism...
  69. ncbi Expression and secretion of human apolipoprotein A-I in the heart
    Nadine Baroukh
    Unité d Expression des Gènes Eucaryotes, Institut Pasteur, Paris, France
    FEBS Lett 557:39-44. 2004
    ..From these novel findings, new insights into the role and function of apoA-I can be extrapolated...
  70. doi The nuclear receptor Rev-erbalpha is a liver X receptor (LXR) target gene driving a negative feedback loop on select LXR-induced pathways in human macrophages
    Coralie Fontaine
    Institut National de la Sante et de la Recherche Medicale, Unité 545, Institut Pasteur de Lille, 1, rue du Professeur Calmette, Boite Postale 245, Lille 59019, France
    Mol Endocrinol 22:1797-811. 2008
    ..These data identify Rev-erbalpha as a new LXR target gene, inhibiting LXR-induction of TLR-4 in a negative transcriptional feedback loop, but not cholesterol homeostasis gene expression...
  71. ncbi Fenofibrate increases homocystinemia through a PPARalpha-mediated mechanism
    Gerald Luc
    Department of Atherosclerosis, Institute Pasteur of Lille, France and Faculté de Pharmacie, University Lille II, France
    J Cardiovasc Pharmacol 43:452-3. 2004
    ....
  72. ncbi FXR-deficiency confers increased susceptibility to torpor
    Bertrand Cariou
    Institut Pasteur de Lille, Departement d Atherosclerose, Lille F 59019, France
    FEBS Lett 581:5191-8. 2007
    ..These results identify FXR as a modulator of energy homeostasis...
  73. ncbi Niemann-Pick C1 like 1 gene expression is down-regulated by LXR activators in the intestine
    Caroline Duval
    Institut Pasteur de Lille, Departement d Atherosclerose, Lille F 59019, France
    Biochem Biophys Res Commun 340:1259-63. 2006
    ..In conclusion, the present study identifies NPC1L1 as a novel LXR target gene further supporting a crucial role of LXR in intestinal cholesterol homeostasis...
  74. ncbi Apolipoprotein E knockout mice over-expressing human tissue inhibitor of metalloproteinase 1 are protected against aneurysm formation but not against atherosclerotic plaque development
    Clarisse Cuaz-Pérolin
    INSERM U 545, Institut Pasteur de Lille, Departement d Atherosclerose, Lille, France
    J Vasc Res 43:493-501. 2006
    ..We investigated the effect of plasma levels of human tissue inhibitor of metalloproteinase (hTIMP)-1 on arterial lesion development and aneurysm formation in apolipoprotein-E-deficient mice (ApoE(-/-))...
  75. pmc Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis
    Philippe Lefebvre
    Departement d Atherosclerose, Institut Pasteur de Lille, INSERM U545, and Université de Lille 2, Lille, France
    J Clin Invest 116:571-80. 2006
    ..This Review will focus on the mechanisms of action of PPARalpha in metabolic diseases and their associated vascular pathologies...
  76. doi Glucose regulates the expression of the apolipoprotein A5 gene
    Maxime Nowak
    Institut Pasteur de Lille, Departement d Atherosclerose, Lille, France
    J Mol Biol 380:789-98. 2008
    ..We demonstrate that the APOA5 gene is up regulated by d-glucose and USF through phosphatase activation. These findings may provide a new cross-talk between glucose and lipid metabolism...
  77. doi Atheroprotective effect of human apolipoprotein A5 in a mouse model of mixed dyslipidemia
    Roxane M Mansouri
    INSERM, U545, Institut Pasteur de Lille, Lille F 59019, France
    Circ Res 103:450-3. 2008
    ..These results identify an atheroprotective role of hApoA5 in a mouse model of mixed dyslipidemia...
  78. ncbi Postprandial leptin response to carbohydrate and fat meals in obese women
    Monique Romon
    Service de Nutrition, Faculté de Médecine M R, Institut Pasteur Lille, Lille Cedex, France
    J Am Coll Nutr 22:247-51. 2003
    ..To assess the postprandial leptin responses to a carbohydrate and a fatty meal in obese subjects and its association with postprandial insulin response...
  79. ncbi Liver X receptors and the control of cholesterol homeostasis: potential therapeutic targets for the treatment of atherosclerosis
    Lesley J Millatt
    Faculte de Pharmacie, Universite de Lille II, Lille, France
    Biochim Biophys Acta 1631:107-18. 2003
    ..However, we also draw attention to the possible undesirable side-effects of LXR activation, and thus the potential interest of developing target gene-specific LXR agonists, or agonists that are specific for only one LXR isoform...
  80. ncbi Paullinia pinnata extracts rich in polyphenols promote vascular relaxation via endothelium-dependent mechanisms
    Alexis Zamble
    Laboratoire de Pharmacognosie, Faculte de Pharmacie, Universite de Lille 2, Lille, France
    J Cardiovasc Pharmacol 47:599-608. 2006
    ..It could be suggested that the arterial relaxation induced by both extracts could be mainly linked to their capacities to inhibit nitric oxide oxidation through their antioxidant properties...
  81. ncbi Regulation of human apoA-I by gemfibrozil and fenofibrate through selective peroxisome proliferator-activated receptor alpha modulation
    Hélène Duez
    UR545INSERM, Departement d Atherosclerose, Institut Pasteur Lille and Faculté de Pharmacie, Université de Lille2, France
    Arterioscler Thromb Vasc Biol 25:585-91. 2005
    ..The objective of this trial was to study the effects of fenofibrate (FF) and gemfibrozil (GF), the most commonly used fibrates, on high-density lipoprotein (HDL) and apolipoprotein (apo) A-I...
  82. ncbi Apolipoprotein A5, a crucial determinant of plasma triglyceride levels, is highly responsive to peroxisome proliferator-activated receptor alpha activators
    Ngoc Vu-Dac
    Departement d Atherosclerose, U 545 INSERM, Institut Pasteur de Lille and Faculté de Pharmacie de Lille, 1 rue Calmette BP 245, 59019 Lille Cedex, France
    J Biol Chem 278:17982-5. 2003
    ..These findings demonstrate that APOA5 is a highly responsive peroxisome proliferator-activated receptor alpha target gene and support its role as a major mediator for how fibrates reduce plasma triglycerides in humans...
  83. ncbi Genetically-engineered animals as research models for atherosclerosis: their use for the characterization of PPAR agonists in the treatment of cardiometabolic disorders
    Catherine Fievet
    Institut Pasteur de Lille, Departement d Atherosclerose, Lille, F 59019 France
    Front Biosci 12:4132-56. 2007
    ....
  84. doi Liver X receptor activation induces the uptake of cholesteryl esters from high density lipoproteins in primary human macrophages
    Stephanie Bultel
    Institut Pasteur de Lille, INSERM, U545, Universite de Lille 2, Faculté de Pharmacie et de Médecine Lille, Lille, France
    Arterioscler Thromb Vasc Biol 28:2288-95. 2008
    ..However, implication of LXRs in the selective uptake of cholesteryl esters from lipoproteins in human macrophages has never been reported...
  85. ncbi Plasma cystatin-C and development of coronary heart disease: The PRIME Study
    Gerald Luc
    Department of Atherosclerosis, SERLIA INSERM UR545, Institut Pasteur de Lille, 1, rue du Professeur Calmette, 59019 Lille Cedex, France and University Lille II, France
    Atherosclerosis 185:375-80. 2006
    ..Cystatin-C is not a more predictive risk marker of CHD than CRP or interleukin-6, but could be useful in detecting moderate chronic renal disease...
  86. ncbi Peroxisome proliferator-activated receptors: regulation of transcriptional activities and roles in inflammation
    Christophe Blanquart
    UR 545 INSERM, Departement d Atherosclerose, Institut Pasteur de Lille, 1 rue Calmette, 59019 Lille, France
    J Steroid Biochem Mol Biol 85:267-73. 2003
    ..A better understanding of the mechanism of action of PPARs could improve the design of more specific and more efficient novel drugs. Molecules with dissociated effects could be useful for the treatment of lipid disorders or inflammation...
  87. ncbi Pleiotropic effects of fibrates
    Giulia Chinetti-Gbaguidi
    UR 545 INSERM, Institut Pasteur de Lille, 1 rue Calmette BP245, 59019 Lille, France
    Curr Atheroscler Rep 7:396-401. 2005
    ..These combined actions translate into clinical benefit as demonstrated by the reduction in cardiovascular morbidity and mortality in primary and secondary intervention trials...
  88. ncbi The PPARalpha activator fenofibrate slows down the progression of the left ventricular dysfunction in porcine tachycardia-induced cardiomyopathy
    Francois Brigadeau
    Department of Experimental Pharmacology EA 1046, University Hospital of Cardiology, Faculty of Medicine, University of Lille 2, Lille, France
    J Cardiovasc Pharmacol 49:408-15. 2007
    ..These data suggest that a clinically relevant dose of fenofibrate does not accelerate but slows down heart failure development in the model of pacing-induced heart failure in large mammals...
  89. ncbi The increase of apolipoprotein A-V during postprandial lipemia parallels the response of triglyceride-rich lipoproteins in type 2 diabetes: no relationship between apoA-V and postheparin plasma lipolytic activity
    Juhani Kahri
    Division of Cardiology, Helsinki University Hospital, Biomedicum, Helsinki, Finland
    Diabetes Care 30:2083-5. 2007
  90. ncbi Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells
    Nikolaus Marx
    Department of Internal Medicine II Cardiology, University of Ulm, Robert Koch Str 8, D 89081 Ulm, Germany
    Circ Res 94:1168-78. 2004
    ..This review will focus on the role of PPARs in the vasculature and summarize the present understanding of their effects on atherogenesis and its cardiovascular complications...
  91. pmc Increased ABCA1 activity protects against atherosclerosis
    Roshni R Singaraja
    Centre for Molecular Medicine and Therapeutics, Children s and Women s Hospital, University of British Columbia, 950 West 28th Avenue, Vancouver, British Columbia V5Z 4H4, Canada
    J Clin Invest 110:35-42. 2002
    ..Lipid analysis of HDL particles from BAC(+)ApoE(-/-) mice revealed an increase in phospholipid levels, which was correlated significantly with their ability to enhance cholesterol efflux...
  92. ncbi HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events
    Philip Barter
    Heart Research Institute, Sydney, Australia
    N Engl J Med 357:1301-10. 2007
    ..High-density lipoprotein (HDL) cholesterol levels are a strong inverse predictor of cardiovascular events. However, it is not clear whether this association is maintained at very low levels of low-density lipoprotein (LDL) cholesterol...
  93. ncbi Apolipoprotein A-V gene polymorphisms in subjects with metabolic syndrome
    Loredan Stefan Niculescu
    Department of Lipoproteins and Atherosclerosis, Institute of Cellular Biology and Pathology Nicolae Simionescu, Bucharest, Romania
    Clin Chem Lab Med 45:1133-9. 2007
    ..Genetic variation at the apolipoprotein A-V locus, recently discovered proximal to the APOA1/C3/A4 gene cluster, is associated with elevated triglyceride concentrations, a risk factor for atherosclerosis...
  94. ncbi Alterations of lipids and apolipoprotein CIII in very low density lipoprotein subspecies in type 2 diabetes
    Anne Hiukka
    Department of Medicine, Division of Cardiology, Helsinki University Hospital and Biomedicum, Haartmaninkatu 8, 00029, Helsinki, Finland
    Diabetologia 48:1207-15. 2005
    ..The aim of the study was to examine the distribution and composition of VLDL subspecies in type 2 diabetes...
  95. ncbi Peroxisome proliferator-activated receptor-alpha activation as a mechanism of preventive neuroprotection induced by chronic fenofibrate treatment
    Dominique Deplanque
    Laboratoire de Pharmacologie, Universite de Lille 2, Faculté deMédecine, Lille, 59045 France
    J Neurosci 23:6264-71. 2003
    ....
  96. ncbi [PPAR gamma: a major nuclear receptor in adipogenesis]
    Philippe Gervois
    Med Sci (Paris) 19:20-2. 2003
  97. ncbi The farnesoid X receptor induces very low density lipoprotein receptor gene expression
    Audrey Sirvent
    GENFIT, Parc Eurasante, Loos, France
    FEBS Lett 566:173-7. 2004
    ....
  98. ncbi Farnesoid X receptor represses hepatic lipase gene expression
    Audrey Sirvent
    GENFIT, Parc Eurasante, Loos, France
    J Lipid Res 45:2110-5. 2004
    ..Taken together, these results identify HL as a new FXR-regulated gene in human liver cells. In view of the role of HL in plasma lipoprotein metabolism, our results further emphasize the central role of FXR in lipid homeostasis...
  99. ncbi [Pharmacology of PPARalpha, PPARgamma and dual PPARalpha/gamma agonists in clinical development]
    Daniel Duran-Sandoval
    INSERM U 545, Departement d Atherosclerose, Institut Pasteur de Lille, 1, rue du Professeur Calmette, 59019 Lille, France
    Med Sci (Paris) 19:819-25. 2003
    ..In this review, we will discuss the mode of action of fibrates and TZD and we will present an overview on PPAR ligands under development...
  100. pmc Insulin-mediated down-regulation of apolipoprotein A5 gene expression through the phosphatidylinositol 3-kinase pathway: role of upstream stimulatory factor
    Maxime Nowak
    Parc Eurasanté Université de Lille 2, 885 Ave Eugène Avinée, 59120 Loos, France
    Mol Cell Biol 25:1537-48. 2005
    ..The effect of exogenous hyperinsulinemia in men showed a decrease in the plasma ApoAV level. These results suggest a potential contribution of the APOA5 gene in hypertriglyceridemia associated with hyperinsulinemia...
  101. ncbi Intensive lipid lowering with atorvastatin in patients with stable coronary disease
    John C LaRosa
    State University of New York Health Science Center, Brooklyn, NY 11203, USA
    N Engl J Med 352:1425-35. 2005
    ..We prospectively assessed the efficacy and safety of lowering LDL cholesterol levels below 100 mg per deciliter (2.6 mmol per liter) in patients with stable coronary heart disease (CHD)...